Mottiwala Aziz
Chief Commercial Officer
Mottiwala Aziz has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Mar 19, 2026.
On the most recent filing, Mottiwala Aziz is listed as Chief Commercial Officer at Tarsus Pharmaceuticals, Inc. Inside the rolling window, Mottiwala Aziz reported no open-market purchases and 3 open-market sales totaling $893K in TARS. The largest disclosed transaction in the window is a sale of 4,286 TARS shares on Mar 17, 2026, worth $298K.
Companies traded
Other insiders at TARS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$893K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Mottiwala Aziz made?
Mottiwala Aziz has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company since 2026.
Which companies does Mottiwala Aziz trade?
Mottiwala Aziz has filed SEC Form 4 disclosures for 1 company, including TARS.
When was Mottiwala Aziz's most recent SEC Form 4 filing?
Mottiwala Aziz's most recent SEC Form 4 filing on Tracefour is dated Mar 19, 2026.
What is Mottiwala Aziz's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Mottiwala Aziz is listed as Chief Commercial Officer.
What is Mottiwala Aziz's total buy and sell value in the current window?
Inside the rolling retention window, Mottiwala Aziz bought $0 and sold $893K based on SEC Form 4 filings.
What was Mottiwala Aziz's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 4,286 TARS shares on 2026-03-17, worth $298K, per SEC Form 4 filings.